Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 9/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656157 | 0.94 | ENPP1 (0.58) | ENPP1LRRK2CHRM4PDGFRBSRC | |
| SCHEMBL23726518 | 0.87 | ENPP1 (0.72) | ENPP1LRRK2PDGFRBSRC | |
| SCHEMBL30080119 | 0.87 | ENPP1 (0.72) | ENPP1LRRK2PDGFRBSRC | |
| SCHEMBL25656156 | 0.85 | ENPP1 (0.72) | ENPP1LRRK2PDGFRB | |
| SCHEMBL25656016 | 0.83 | ENPP1 (0.61) | ENPP1LRRK2PDGFRBABCB1ABCC1 | |
| SCHEMBL25656160 | 0.83 | ENPP1 (0.80) | ENPP1LRRK2PDGFRBSRC | |
| SCHEMBL25656104 | 0.83 | LRRK2 (0.57) | ENPP1LRRK2CHRM4ABCB1ABCC1 | |
| SCHEMBL25656154 | 0.82 | ENPP1 (0.80) | ENPP1LRRK2PDGFRBSRC | |
| SCHEMBL25656015 | 0.82 | ENPP1 (0.68) | ENPP1LRRK2PDGFRBSRC | |
| SCHEMBL30080137 | 0.81 | ENPP1 (0.75) | ENPP1PDGFRBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885LRRK2 3715/4885CHRM4 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.